Lincoln, Nebraska, Nov. 17, 2023 (GLOBE NEWSWIRE) -- National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, January 12, 2024, to shareholders of record as of the close of business on Friday, December 29, 2023.
For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health’s patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. NRC Health is ranked #1 for Patient Experience Improvement in the 2023 Best in KLAS report.
Last Trade: | US$11.79 |
Daily Change: | 0.11 0.94 |
Daily Volume: | 53,066 |
Market Cap: | US$271.880M |
July 28, 2025 April 28, 2025 February 25, 2025 January 27, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load